John T Reilly

Summary

Affiliation: University of Sheffield
Country: UK

Publications

  1. ncbi request reprint Chronic neutrophilic leukaemia: a distinct clinical entity?
    John T Reilly
    Molecular Haematology Unit, Division of Molecular and Genetic Medicine, Royal Hallamshire Hospital, Sheffield, UK
    Br J Haematol 116:10-8. 2002
  2. ncbi request reprint FLT3 and its role in the pathogenesis of acute myeloid leukaemia
    John T Reilly
    Molecular Haematology Unit, Division of Molecular and Genetic Medicine, M Floor, Royal Hallamshire Hospital, Sheffield S10 2JF, UK
    Leuk Lymphoma 44:1-7. 2003
  3. doi request reprint Current treatment practices for essential thrombocythemia: survey results from European hematologists/oncologists
    John T Reilly
    Department of Haematology, Royal Hallamshire Hospital, Sheffield, UK
    Hematology 17:187-92. 2012
  4. doi request reprint Guideline for the diagnosis and management of myelofibrosis
    John T Reilly
    Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
    Br J Haematol 158:453-71. 2012
  5. ncbi request reprint Pathogenesis of acute myeloid leukaemia and inv(16)(p13;q22): a paradigm for understanding leukaemogenesis?
    John T Reilly
    Molecular Haematology Unit, Division of Molecular and Genetic Medicine, Royal Hallamshire Hospital, Sheffield, UK
    Br J Haematol 128:18-34. 2005
  6. ncbi request reprint Cytogenetic and molecular genetic abnormalities in agnogenic myeloid metaplasia
    John T Reilly
    Academic Unit of Haematology, Henry Wellcome Laboratories for Medical Research, Sheffield, UK
    Semin Oncol 32:359-64. 2005
  7. ncbi request reprint Cytogenetic and molecular genetic aspects of idiopathic myelofibrosis
    John T Reilly
    Academic Unit of Haematology, Division of Genomic Medicine, Royal Hallamshire Hospital, Sheffield, UK
    Acta Haematol 108:113-9. 2002
  8. ncbi request reprint Receptor tyrosine kinases in normal and malignant haematopoiesis
    John T Reilly
    Royal Hallamshire Hospital, Sheffield, UK
    Blood Rev 17:241-8. 2003
  9. ncbi request reprint Class III receptor tyrosine kinases: role in leukaemogenesis
    John T Reilly
    Molecular Haematology Unit, Division of Molecular and Genetic Medicine, Royal Hallamshire Hospital, Sheffield, UK
    Br J Haematol 116:744-57. 2002
  10. doi request reprint Anagrelide for the treatment of essential thrombocythemia: a survey among European hematologists/oncologists
    John T Reilly
    Department of Haematology, Royal Hallamshire Hospital, Sheffield, UK
    Hematology 14:1-10. 2009

Detail Information

Publications50

  1. ncbi request reprint Chronic neutrophilic leukaemia: a distinct clinical entity?
    John T Reilly
    Molecular Haematology Unit, Division of Molecular and Genetic Medicine, Royal Hallamshire Hospital, Sheffield, UK
    Br J Haematol 116:10-8. 2002
  2. ncbi request reprint FLT3 and its role in the pathogenesis of acute myeloid leukaemia
    John T Reilly
    Molecular Haematology Unit, Division of Molecular and Genetic Medicine, M Floor, Royal Hallamshire Hospital, Sheffield S10 2JF, UK
    Leuk Lymphoma 44:1-7. 2003
    ..FLT3, therefore, is a potentially important molecular target for AML therapy and already phase I clinical trials have been initiated...
  3. doi request reprint Current treatment practices for essential thrombocythemia: survey results from European hematologists/oncologists
    John T Reilly
    Department of Haematology, Royal Hallamshire Hospital, Sheffield, UK
    Hematology 17:187-92. 2012
    ..Further studies are needed to determine whether current practices used by physicians for the treatment of ET are consistent with consensus guidelines...
  4. doi request reprint Guideline for the diagnosis and management of myelofibrosis
    John T Reilly
    Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
    Br J Haematol 158:453-71. 2012
    ....
  5. ncbi request reprint Pathogenesis of acute myeloid leukaemia and inv(16)(p13;q22): a paradigm for understanding leukaemogenesis?
    John T Reilly
    Molecular Haematology Unit, Division of Molecular and Genetic Medicine, Royal Hallamshire Hospital, Sheffield, UK
    Br J Haematol 128:18-34. 2005
    ..This paper reviews the recent advances in the molecular pathology of AML and inv(16) and discusses possible therapeutic implications of the current pathogenetic model...
  6. ncbi request reprint Cytogenetic and molecular genetic abnormalities in agnogenic myeloid metaplasia
    John T Reilly
    Academic Unit of Haematology, Henry Wellcome Laboratories for Medical Research, Sheffield, UK
    Semin Oncol 32:359-64. 2005
    ..Targeted gene screening has revealed only rare oncogenic point mutations in N-RAS, p53, and c-KIT...
  7. ncbi request reprint Cytogenetic and molecular genetic aspects of idiopathic myelofibrosis
    John T Reilly
    Academic Unit of Haematology, Division of Genomic Medicine, Royal Hallamshire Hospital, Sheffield, UK
    Acta Haematol 108:113-9. 2002
    ..Cytogenetic abnormalities have been associated with prognosis and to a lack of treatment response to androgens. Oncogene mutations are rare and include point mutations in N-RAS, c-KIT and TP53...
  8. ncbi request reprint Receptor tyrosine kinases in normal and malignant haematopoiesis
    John T Reilly
    Royal Hallamshire Hospital, Sheffield, UK
    Blood Rev 17:241-8. 2003
    ..It is to be hoped that this knowledge will provide important new insights for targeted therapy in leukaemia...
  9. ncbi request reprint Class III receptor tyrosine kinases: role in leukaemogenesis
    John T Reilly
    Molecular Haematology Unit, Division of Molecular and Genetic Medicine, Royal Hallamshire Hospital, Sheffield, UK
    Br J Haematol 116:744-57. 2002
  10. doi request reprint Anagrelide for the treatment of essential thrombocythemia: a survey among European hematologists/oncologists
    John T Reilly
    Department of Haematology, Royal Hallamshire Hospital, Sheffield, UK
    Hematology 14:1-10. 2009
    ..2%) patients prior to switching to anagrelide. In conclusion, this survey provides a useful insight into the epidemiology of ET and current prescribing patterns for anagrelide in Europe...
  11. pmc UK NEQAS for leucocyte immunophenotyping: the first 10 years
    J T Reilly
    UK NEQAS for Leucocyte Immunophenotyping, Department of Haematology, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK
    J Clin Pathol 54:508-11. 2001
    ..This major technological advancement has enabled the distribution of specimens for EQA purposes on a global scale that have minimal matrix effect and behave in a manner identical to fresh blood for several months after stabilisation...
  12. doi request reprint Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs)
    J T Reilly
    Department of Haematology, Royal Hallamshire Hospital, Sheffield, UK
    Leukemia 22:1818-27. 2008
    ..A brief overview is given of the cytogenetic findings in the individual diseases, followed by a more detailed discussion of the possible pathogenetic consequences of specific abnormalities and their impact on prognosis...
  13. ncbi request reprint Flow rate calibration II: a clinical evaluation study using PanLeucoGating as a single-platform protocol
    Ian Storie
    UK NEQAS for Leucocyte Immunophenotyping, Royal Hallamshire Hospital, Sheffield, United Kingdom
    Cytometry B Clin Cytom 55:8-13. 2003
    ....
  14. ncbi request reprint Perfect count: a novel approach for the single platform enumeration of absolute CD4+ T-lymphocytes
    Ian Storie
    UK NEQAS for Leucocyte Immunophenotyping, Royal Hallamshire Hospital, Sheffield, United Kingdom
    Cytometry B Clin Cytom 57:47-52. 2004
    ..quot; However, although single-platform, bead-based, sample acquisition requires the ratio of beads to cells to remain unchanged, there is no available method, until recently, to monitor this...
  15. ncbi request reprint Flow rate calibration. III. The use of stabilized biostandards to calibrate the flow rate and calculate absolute CD4+ T-cell counts
    Clare L Walker
    UK NEQAS for Leucocyte Immunophenotyping, Department of Haematology, Royal Hallamshire Hospital, Sheffield
    Cytometry B Clin Cytom 70:154-62. 2006
    ..Such material has advantages over latex bead technology as it can act as a full process control as well as having the same matrix and viscosity characteristics as the test material, thus removing the need for a CF...
  16. doi request reprint ISHAGE protocol: are we doing it correctly?
    Alison Whitby
    UK NEQAS for Leucocyte Immunophenotyping, Department of Haematology, Royal Hallamshire Hospital, Sheffield S10 2QN
    Cytometry B Clin Cytom 82:9-17. 2012
    ..This prompted UK NEQAS to question whether other laboratories were making similar errors and, if so, how this might affect individual EQA performance...
  17. ncbi request reprint Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias
    Rory S Care
    Academic Unit of Haematology, Division of Genomic Medicine, Royal Hallamshire Hospital, Sheffield, UK
    Br J Haematol 121:775-7. 2003
    ..6%) with t(8;21) AML. All mutations were mutually exclusive; 40% of inv(16) AML patients possessed either a c-KIT or FLT3 mutation. c-KIT exon 8 mutations were shown to be a significant factor adversely affecting relapse rate...
  18. ncbi request reprint The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels
    Melanie J Percy
    Department of Haematology, Floor C, Tower Block, Belfast City Hospital, Northern Ireland, UK
    Haematologica 92:1607-14. 2007
    ..The aims of this study were to assess the prevalence of JAK2 exon 12 mutations in IE patients, and to determine the associated clinicopathological features...
  19. doi request reprint VERITAS?: A time for VERIQASâ„¢ and a new approach to training, education, and the quality assessment of CD4+ T lymphocyte counting (I)
    David Barnett
    UK NEQAS for Leucocyte Immunophenotyping, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, England
    Cytometry B Clin Cytom 82:93-100. 2012
    ....
  20. ncbi request reprint Mutational analysis of class III receptor tyrosine kinases (C-KIT, C-FMS, FLT3) in idiopathic myelofibrosis
    Faisel M Abu-Duhier
    Academic Unit of Haematology, Division of Genomic Medicine, Royal Hallamshire Hospital, Sheffield, UK
    Br J Haematol 120:464-70. 2003
    ..Therefore, in contrast to acute myeloid leukaemia, mutations in RTKs class III do not appear to play a significant pathogenetic role in idiopathic myelofibrosis...
  21. ncbi request reprint Reduction of intra- and interlaboratory variation in CD34+ stem cell enumeration using stable test material, standard protocols and targeted training. DK34 Task Force of the European Working Group of Clinical Cell Analysis (EWGCCA)
    D Barnett
    UK NEQAS for Leucocyte Immunophenotyping, Department of Haematology, Royal Hallamshire Hospital, Sheffield, UK
    Br J Haematol 108:784-92. 2000
    ..Thus, the use of a common standardized protocol and targeted training significantly reduced intra- and interlaboratory CD34+ cell count variation...
  22. ncbi request reprint Absolute CD4+ T-lymphocyte and CD34+ stem cell counts by single-platform flow cytometry: the way forward
    D Barnett
    UK NEQAS for Leucocyte Immunophenotyping, Department of Haematology, Royal Hallamshire Hospital, Sheffield
    Br J Haematol 106:1059-62. 1999
    ....
  23. ncbi request reprint Standardization of lymphocyte antibody binding capacity - a multi-centre study
    D Barnett
    UK NEQAS for Leucocyte Immunophenotyping, Royal Hallamshire Hospital co ordinating centre, Sheffield, UK
    Clin Lab Haematol 22:89-96. 2000
    ..Furthermore, using such an approach, a normal range was established for CD3, CD4 CD8 and CD19. These antigens appear to be expressed in a hierarchical manner, a factor that could be used as a procedural quality control measure...
  24. ncbi request reprint Idiopathic myelofibrosis: pathogenesis to treatment
    John T Reilly
    Academic Unit of Haematology, Division of Genomic Medicine, Royal Hallamshire Hospital, Sheffield, UK
    Hematol Oncol 24:56-63. 2006
    ..This review summarises the recent advances in the disease's pathogenesis and discusses the role of the various therapeutic options...
  25. ncbi request reprint Diagnosis of plasma cell leukaemia: findings of the UK NEQAS for Leucocyte Immunophenotyping scheme
    J J van Veen
    Department of Haematology, Royal Hallamshire Hospital, Sheffield, UK
    Clin Lab Haematol 26:37-42. 2004
    ....
  26. ncbi request reprint Low level leucocyte counting: a critical variable in the validation of leucodepleted blood transfusion components as highlighted by an external quality assessment study
    D Barnett
    UK NEQAS for Leucocyte Immunophenotyping, Department of Haematology, Royal Hallamshire Hospital, Sheffield, UK
    Clin Lab Haematol 23:43-51. 2001
    ..Finally, we demonstrate that stabilized blood preparations can be successfully used to provide a national/international low-level leucocyte EQA scheme...
  27. ncbi request reprint Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study
    Peter J Campbell
    Department of Haematology, University of Cambridge, UK
    Lancet 366:1945-53. 2005
    ..We aimed to assess whether patients with the mutation are biologically distinct from those without, and why the same mutation is associated with different disease phenotypes...
  28. ncbi request reprint Neutrophil inclusions in cryoglobulinaemia
    Stuart T Laidlaw
    Department of Haematology, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK
    Br J Haematol 122:344. 2003
  29. pmc Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms
    Philip A Beer
    Cambridge Institute for Medical Research, Department of Haematology, University of Cambridge, Hills Road, Cambridge, UK
    Haematologica 95:2153-6. 2010
    ....
  30. ncbi request reprint Detection of cryptic MLL insertions using a commercial dual-color fluorescence in situ hybridization probe
    Michael J Dyson
    North Trent Cytogenetics Department, Sheffield Children s NHS Trust, Western Bank, S10 2TH, Sheffield, UK
    Cancer Genet Cytogenet 147:81-3. 2003
    ....
  31. ncbi request reprint Flow rate calibration I: a novel approach for performing absolute cell counts
    Ian Storie
    UK NEQAS for Leucocyte Immunophenotyping, Royal Hallamshire Hospital, Sheffield, United Kingdom
    Cytometry B Clin Cytom 55:1-7. 2003
    ..Therefore, if FR is constant, the volume acquired in a fixed time period will also be constant, enabling absolute leucocyte counting using flow rate calibration (FRC)...
  32. doi request reprint The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial
    Alan K Burnett
    Department of Haematology, School of Medicine, Cardiff University Heath Park, Cardiff, UK
    Br J Haematol 145:318-32. 2009
    ..In conclusion, these four interventions have not improved outcomes in older patients. New agents need to be explored and novel trial designs are required to maximise prospects of achieving timely progress...
  33. ncbi request reprint Gains on 9p are common genomic aberrations in idiopathic myelofibrosis: a comparative genomic hybridization study
    O Al-Assar
    Institute for Cancer Studies, Division of Genomic Medicine, Medical School, University of Sheffield, Sheffield, UK
    Br J Haematol 129:66-71. 2005
    ..Gains of 9p were the most frequent finding, occurring in 50% of patients and suggests that genes on 9p may play a crucial role in the pathogenesis of IMF...
  34. ncbi request reprint Fluorescence in situ hybridization analysis of 25 cases of idiopathic myelofibrosis and two cases of secondary myelofibrosis: monoallelic loss of RB1, D13S319 and D13S25 loci associated with cytogenetic deletion and translocation involving 13q14
    E J Sinclair
    North Trent Cytogenetics Service, and Department of Haematology, Royal Hallamshire Hospital, Sheffield, UK
    Br J Haematol 113:365-8. 2001
    ..In addition, the genetic loss associated with cytogenetic 13q14 deletions or reciprocal translocations involving 13q14 is large and encompasses the gene-rich region around RB1, D13S319 and D13S25...
  35. ncbi request reprint Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis
    Mary F McMullin
    Department of Haematology, Queen s University, Belfast, Belfast City Hospital, Belfast, UK
    Br J Haematol 130:174-95. 2005
  36. ncbi request reprint Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel
    Ayalew Tefferi
    Mayo Clinic, Rochester, MN 55905, USA
    Blood 110:1092-7. 2007
    ....
  37. ncbi request reprint Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation
    Peter J Campbell
    Department of Haematology, University of Cambridge, Cambridge, United Kingdom
    Blood 108:3548-55. 2006
    ..In 3 patients the leukemic cells were V617F(-), suggesting that in these patients the leukemia arose in a V617F(-) cell...
  38. ncbi request reprint Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and
    Ruben A Mesa
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 31:737-40. 2007
    ....
  39. ncbi request reprint International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)
    Ayalew Tefferi
    Mayo Clinic, 200 First Street SW, Rochester MN 55905, USA
    Blood 108:1497-503. 2006
    ..Bone marrow histologic and hematologic remissions characterize CR and CR/PR, respectively. The panel agreed that the CI response category is applicable only to patients with moderate to severe cytopenia or splenomegaly...
  40. ncbi request reprint FLT3 internal tandem duplication mutations are rare in agnogenic myeloid metaplasia
    Faisal M Abu-Duhier
    Blood 100:364. 2002
  41. ncbi request reprint c-FMS mutational analysis in acute myeloid leukaemia
    Faisel M Abu-Duhier
    Br J Haematol 123:749-50. 2003
  42. ncbi request reprint Second hit mutations in the RTK/RAS signaling pathway in acute myeloid leukemia with inv(16)
    Peter J M Valk
    Haematologica 89:106. 2004
  43. ncbi request reprint Der(6)t(1;6)(q21-23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia
    David Dingli
    Division of Hematology and Department of Internal Medicine, Mayo Clinic Rochester, MN, USA
    Br J Haematol 130:229-32. 2005
    ..In a preliminary fluorescence in situ hybridization study, the breakpoints on chromosome 6 in two additional cases were found to be telomeric to the gene for 51 kDa FK506-binding protein (FKBP51)...
  44. ncbi request reprint V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis
    Peter J Campbell
    Department of Haematology, University of Cambridge, United Kingdom
    Blood 107:2098-100. 2006
    ..Patients positive for V617F were less likely to require blood transfusion during follow-up (P = .03). Despite this, patients positive for V617F had poorer overall survival, even after correction for confounding factors (P = .01)...
  45. ncbi request reprint Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET)
    Giovanni Barosi
    Laboratorio di Epidemiologia Clinica, IRCCS Policlinico S Matteo, Viale Golgi 19, 27100 Pavia, Italy
    Blood 106:2849-53. 2005
    ..A histologic response was defined by changes in bone marrow fibrosis and cellularity grades. The combined use of these response definitions should help standardize the design and reporting of future clinical studies in MMM...
  46. ncbi request reprint Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
    Claire N Harrison
    Department of Haematology, University of Cambridge, and Addenbrooke s National Health Service Trust, Cambridge, United Kingdom
    N Engl J Med 353:33-45. 2005
    ..We conducted a randomized comparison of hydroxyurea with anagrelide in the treatment of essential thrombocythemia...
  47. doi request reprint Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders
    Nasios Fourouclas
    Haemato oncology, Diagnostic Service, Department, of Haematology, Addenbrooke s, Hospital, Hills Road, Cambridge, CB2 0QQ, UK
    Haematologica 93:1635-44. 2008
    ....
  48. ncbi request reprint The incidence of the JAK2 V617F mutation in patients with idiopathic erythrocytosis
    Melanie J Percy
    Haematologica 91:413-4. 2006
    ..One patient (1.6%) was found to have this mutation, and has remained stable for 9 years, suggesting that the JAK2 V617F mutation is rare in patients with idiopathic erythrocytosis...
  49. doi request reprint MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort
    Philip A Beer
    Department of Haematology, University of Cambridge, Cambridge, United Kingdom
    Blood 112:141-9. 2008
    ..MPL mutations lacked prognostic significance with respect to thrombosis, major hemorrhage, myelofibrotic transformation or survival...
  50. ncbi request reprint Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options
    Ruben A Mesa
    Laboratory of Clinical Epidemiology, IRCCS Policlinico S Matteo, Pavia, Italy
    Best Pract Res Clin Haematol 19:495-517. 2006
    ..Modern therapy remains palliative but allogeneic stem cell transplantation might be curative to a selected group of patients. This chapter reviews both the old and the new therapy with regard to non-transplant treatment options for MMM...